Patent ID: 8507464

Claim:
A compound of formula (I): wherein Y 1 is O, S, NR 6 or NSO 2 R 6 Y 2 is O, S, NR 6 , NCOR 6 , or NSO 2 R 6 wherein each R 6 is independently (C 1 -C 6 )alkyl, C 1 -C 6 heteroalkyl, aryl, or heteroaryl; R 1 is a Trigger, T, having the formula L-Z 3 ; L is selected from the group consisting of: —[C(Z 1 ) 2 —Y 3 ] v —[C(═O)—O)] q —[C(Z 1 ) 2 —Z 2 —Y 4 ] u —[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )] g ; —[C(Z 1 ) 2 —Y 3 ] v —(S(═O) 2 ) q —[C(Z 1 ) 2 —Z 2 —Y 4 ] u —[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )] g ; —[C(Z 1 ) 2 —Y 3 ]—[C(Z 1 ) 2 —Z 2 —Y 4 ]—[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )]—; —[C(Z 1 ) 2 —Y 3 ]—[C(Z 1 ) 2 ] z —[C(Z 1 )═C(Z 1 )]—; —[C(Z 1 ) 2 —Y 3 ]—[C(Z 1 ) 2 ] Z —; —[C(Z 1 ) 2 —Y 3 ]—(C(═O)—O)—[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )]—; —[C(Z 1 ) 2 —Y 3 ]—(C(═O)—O)—[C(Z 1 ) 2 ] Z —; —[C(Z 1 ) 2 —Y 3 ]—(C(═O)—O)—[C(Z 1 ) 2] Z —[C(Z 1 )═C(Z 1 )]—; —[C(Z 1 ) 2 —Z 2 —Y 4 ]—[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )]—; —[C(Z 1 ) 2 ] Z —[C(Z 1 )═C(Z 1 )]—; and —[C(Z 1 ) 2 ] Z : wherein each z, v, q, u, and g independently is 0 or 1; Y 3 is S, O, or NR 7 wherein each R 7 is independently hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, heterocyclyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, aryl, heteroaryl, C 1 -C 6 acyl, C 1 -C 6 heteroacyl, aroyl, or heteroaroyl; Y 4 is O, S, or —NR 7 —C(═O)—O—; each Z 1 independently is hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, aryl, heteroaryl, C 3 -C 8 cycloalkyl, heterocyclyl, C 1 -C 6 acyl, C 1 -C 6 heteroacyl, aroyl, or heteroaroyl; Z 2 is C 1 -C 6 alkylene, C 1 -C 6 heteroalkylene, wherein each X 1 is independently N or CR 8 wherein R 8 is independently hydrogen, OH, OP(═O)(OH) 2 , halogen, nitro, cyano, CHF 2 , CF 3 , CH 2 CF 3 , CO 2 H, amino, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, aryl, CON(R 7 ) 2 , C 1 -C 6 acyl, C 1 -C 6 heteroacyl, aroyl or heteroaroyl; X 2 is NR 7 , S, or O; and Z 3 is a bioreductive group having a formula selected from the group consisting of: with the proviso that in formula (I): (a) NR 2 R 3 is NHR 3 ; NR 4 R 5 is NHR 5 and R 3 and R 5 independently are selected from the group consisting of 2-haloalkyl, 2- C 1 -C 6 alkylsulfonyloxyalkyl, heteroalkylsulfonyloxyalkyl, 2-arylsulfonyloxyalkyl, and 2-heteroarylsulfonyloxyalkyl; (b) NR 2 R 3 is NHR 3 ; and R 3 independently is selected from the group consisting of 2-haloalkyl, 2-C 1 -C 6 alkylsulfonyloxyalkyl, 2-heteroalkylsulfonyloxyalkyl 2-arylsulfonyloxyalkyl, and 2 -heteroarylsulfonyloxyalkyl; and NR 4 R 5 is or (c) NR 2 R 3 and NR 4 R 5 are an individual stereoisomer or a racemic or non-racemic mixture of stereoisomers, or a pharmaceutically acceptable salt, solvate, or hydrate, thereof.